Study links dapagliflozin to bladder, breast cancers

06/26/2011 | Reuters

Patients treated with the diabetes drug dapagliflozin may develop certain types of cancer, according to company reports from Bristol-Myers Squibb and AstraZeneca, co-makers of the drug. About nine bladder cancer and nine breast cancer incidences were noted in participants on dapagliflozin therapy, experts said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA